Literature DB >> 18175346

Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT.

Marcus M Unger1, Jens C Möller, Karin Stiasny-Kolster, Katharina Mankel, Daniela Berg, Uwe Walter, Helmut Hoeffken, Geert Mayer, Wolfgang H Oertel.   

Abstract

Idiopathic rapid-eye-movement (REM) sleep behavior disorder (iRBD) has been suggested to be a risk factor for subsequent development of neurodegenerative disorders, especially Parkinson's disease (PD) and other alpha-synucleinopathies. At present, it is not possible to predict whether or not an iRBD patient will eventually develop PD. Here, we report 5 iRBD patients who underwent a test battery comprising a neurological examination (including UPDRS rating), mini mental state examination testing, transcranial sonography, olfactory function testing, and presynaptic dopamine transporter imaging with FP-CIT-SPECT. Our preliminary data show the diverse pattern of individual combinations of pathological findings when a multimodal assessment approach is applied in this patient group. Large-size longitudinal studies in iRBD patients are required to evaluate the usefulness of diagnostic tests to identify the subgroup of iRBD patients that is prone to develop PD. (c) 2007 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18175346     DOI: 10.1002/mds.21908

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  13 in total

Review 1.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no.

Authors:  Uwe Walter
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

Review 2.  Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease.

Authors:  Bradley F Boeve
Journal:  Lancet Neurol       Date:  2013-04-09       Impact factor: 44.182

3.  Decision making and executive functions in REM sleep behavior disorder.

Authors:  Margarete Delazer; Birgit Högl; Laura Zamarian; Johanna Wenter; Laura Ehrmann; Viola Gschliesser; Elisabeth Brandauer; Werner Poewe; Birgit Frauscher
Journal:  Sleep       Date:  2012-05-01       Impact factor: 5.849

4.  Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions.

Authors:  Marcus M Unger; Marcus Belke; Katja Menzler; Johannes T Heverhagen; Boris Keil; Karin Stiasny-Kolster; Felix Rosenow; Nico J Diederich; Geert Mayer; Jens C Möller; Wolfgang H Oertel; Susanne Knake
Journal:  Sleep       Date:  2010-06       Impact factor: 5.849

Review 5.  [Sonography of the parenchyma in Parkinson's disease].

Authors:  J Hagenah; G Seidel
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

6.  Comparison study of olfactory function and substantia nigra hyperechogenicity in idiopathic REM sleep behavior disorder, Parkinson's disease and normal control.

Authors:  Hee Young Shin; Eun Youn Joo; Seong Tae Kim; Hun-Jong Dhong; Jin Whan Cho
Journal:  Neurol Sci       Date:  2012-07-28       Impact factor: 3.307

Review 7.  Early Parkinson's disease and non-motor issues.

Authors:  K Ray Chaudhuri; Yogini Naidu
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

8.  Transcranial midbrain sonography in narcoleptic subjects with and without concomitant REM sleep behaviour disorder.

Authors:  Marcus M Unger; Jens C Möller; Tim Ohletz; Karin Stiasny-Kolster; Wolfgang H Oertel; Geert Mayer
Journal:  J Neurol       Date:  2009-02-28       Impact factor: 4.849

Review 9.  Prodromal Parkinson disease subtypes - key to understanding heterogeneity.

Authors:  Daniela Berg; Per Borghammer; Seyed-Mohammad Fereshtehnejad; Sebastian Heinzel; Jacob Horsager; Eva Schaeffer; Ronald B Postuma
Journal:  Nat Rev Neurol       Date:  2021-04-20       Impact factor: 42.937

10.  Idiopathic REM sleep behavior disorder as a long-term predictor of neurodegenerative disorders.

Authors:  Stephany Fulda
Journal:  EPMA J       Date:  2011-06-29       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.